{
  "docId": "019de074-7472-72bc-8651-e49cc0d0319c",
  "docSlug": "c2a880ad0c526527fe8aa49c40270224",
  "documentTitle": "Arbutus Biopharma | Investor Presentation Deck | 28 slides",
  "authorId": "arbutus-biopharma",
  "authorName": "Arbutus Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 21,
  "pageCount": 28,
  "prevPage": 20,
  "nextPage": 22,
  "slideType": "traction",
  "function": "show_traction",
  "density": "balanced",
  "nDataPoints": 2,
  "notes": "Includes IC50 value and IFN-y fold increase data from patient samples.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-7472-72bc-8651-e49cc0d0319c/21",
  "deckHref": "/decks/019de074-7472-72bc-8651-e49cc0d0319c",
  "deckJsonHref": "/decks/019de074-7472-72bc-8651-e49cc0d0319c.json",
  "deckAnchorHref": "/decks/019de074-7472-72bc-8651-e49cc0d0319c#slide-21",
  "components": [
    {
      "bbox": {
        "h": 0.06,
        "w": 0.86,
        "x": 0.07,
        "y": 0.18
      },
      "kind": "callout",
      "text": "AB-101 is highly potent with demonstrated activity against PD-L1 in cells from chronic HBV patients",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "59341d90-4d33-4460-9a37-d22428d39214",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.4,
        "x": 0.55,
        "y": 0.35
      },
      "kind": "chart",
      "text": "AB-101 reinvigorates HBV-specific cHBV patient T-cells",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f87221f2-6fd8-4ea1-a145-48c6e0e5d925",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.4,
        "x": 0.07,
        "y": 0.35
      },
      "kind": "chart",
      "text": "AB-101 reduces PD-L1 on the surface of human primary myeloid cells",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ce90339f-6306-4bb1-a911-7a3d16407115",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.15,
        "x": 0.35,
        "y": 0.48
      },
      "kind": "metric",
      "text": "IC50 = 1.9 nM",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "84e3f836-5ea9-47bd-89b0-6410460eaeb9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.8,
        "x": 0.07,
        "y": 0.05
      },
      "kind": "title",
      "text": "AB-101: Small-Molecule Oral PD-L1 Inhibitor for HBV",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8f64d58c-8392-4658-89ba-c3f76b4fb5be",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Chart Selection Guide",
      "slug": "chart-selection-guide",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "403fd3a1-f37e-42e7-9504-c7a8a1bca350",
      "evidence": "chart/line: AB-101 reduces PD-L1 on the surface of human primary myeloid cells",
      "confidence": 0.7
    },
    {
      "name": "Chart Selection Guide",
      "slug": "chart-selection-guide",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "8a118b57-f7d0-4710-9399-b5384e823ce2",
      "evidence": "chart/bar-vertical: AB-101 reinvigorates HBV-specific cHBV patient T-cells",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 28,
      "from": 8,
      "beatId": "8e825e5a-e303-4698-98f8-f2a022a4a5c6",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The document presents Arbutus Biopharma's pipeline, including AB-729, AB-101, and AB-161, as a potential solution (p8-28).",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    },
    {
      "to": 28,
      "from": 17,
      "beatId": "f38a537d-5a41-47d5-be5b-904ed8c0f42a",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Impact & Next Steps",
      "beatSlug": "consultants-gambit-impact-next-steps",
      "evidence": "The document outlines the next steps for AB-729 and other pipeline programs (p17-28).",
      "position": 4,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 22,
      "from": 20,
      "name": "Jobs To Be Done",
      "slug": "53-jobs-to-be-done",
      "bestFor": "Product innovation, market entry, competitive positioning",
      "matchId": "660159c2-70d4-4fb9-adcd-06670ff0292c",
      "evidence": "The document presents Arbutus Biopharma's pipeline, including AB-101 and AB-161, as potential solutions (p20-22).",
      "position": 1,
      "objective": "What are the key challenges in treating HBV?",
      "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit",
      "confidence": 0.6,
      "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}